37.90 -0.01 (-0.03%)
Pre-market: 4:53AM EDT
|Bid||37.11 x 1200|
|Ask||38.24 x 900|
|Day's range||37.24 - 38.03|
|52-week range||24.10 - 46.62|
|Beta (5Y monthly)||0.79|
|PE ratio (TTM)||49.23|
|Earnings date||22 Jul 2020 - 27 Jul 2020|
|Forward dividend & yield||N/A (N/A)|
|1y target est||43.77|
Boston Scientific (BSX) introduces tool for local measurement and visualization of tissue response to RF ablation treatment in the United States.
A slowdown in medical procedures due to the COVID-19 pandemic caused a decline in first-quarter profits at medical device maker Boston Scientific (NYSE: BSX), but the company still managed a small sales gain, and management made encouraging comments about the future in its earnings call Wednesday. Boston Scientific said on the conference call that its business in the first two months of the year had been consistent with its expectations, which were for sales growth of 10% to 12%. The company's cardiovascular business ended Q1 with a 5.5% sales gain, medical/surgical sales grew 1.1%, and rhythm and neurological sales, which support procedures that are more easily delayed, fell 7.2%.
Boston Scientific (BSX) is steadily investing in new technologies as well as the global markets, reflecting its uptick in sales across most geographies in Q4.
Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.
Boston Scientific (BSX) delivered earnings and revenue surprises of 4.55% and -0.62%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Banking on an innovative portfolio across structural heart and coronary therapies, Boston Scientific's (BSX) IC business is expected to have registered strong sales in Q4.
Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.
A series of product launches despite the ongoing regulatory hurdles is likely to favor revenues in the medical products space this earnings season.
Growth in the COPD devices market can be attributed to factors like steadily rising geriatric population, increasing incidence of smoking and chronic respiratory diseases.
Boston Scientific's (BSX) recent takeovers of BTG, NxThera, Claret Medical, VENITI and Augmenix make us optimistic about their positive synergies to be added to the company portfolio.
Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.
Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.